To cure myeloma by fostering research, education and excellence in clinical care worldwide.

Join us for a dynamic educational workshop on the diagnosis, treatment, and monitoring of plasma cell malignancies, including current practices and opportunities for improvement. This workshop will include lectures plus roundtable discussions around hot and controversial topics, featuring point-counterpoint conversations between invited speakers and local hematologists based on both challenging questions and clinical cases.

IMS is pleased to announce that the 6th Annual Immune Effector Cell Therapies in Multiple Myeloma Workshop will take place from March 28-29, 2025 in Boston, MA.

Preliminary Program

This high-impact, 90-minute educational program will focus on the latest evidence for optimizing treatments for Newly Diagnosed patients, including the choice between 3- vs 4-drug regimens and considerations around fitness/frailty. Key concepts will be covered in presentations by senior faculty, along with practice-relevant case-based discussions.

Program

This high-impact, 90-minute educational program will focus on the latest evidence for optimizing treatments for Newly Diagnosed patients, including the choice between 3- vs 4-drug regimens and considerations around fitness/frailty. Key concepts will be covered in presentations by senior faculty, along with practice-relevant case-based discussions.

Program

Join us for a dynamic educational workshop on the diagnosis, treatment, and monitoring of plasma cell malignancies, including current practices and opportunities for improvement. This workshop will include lectures plus roundtable discussions around hot and controversial topics, featuring point-counterpoint conversations between invited speakers and local hematologists based on both challenging questions and clinical cases.

Program 

The IMS Workshop on Genomics was developed in response to the IMS-FDA joint workshop to further consider essential needs in myeloma. The initial invitation-only meeting in 2023 provided an opportunity for myeloma experts from around the world to develop a consensus to define ‘high-risk multiple myeloma’. Building upon this success, the Third IMS Genomics Meeting will be a public meeting led by global myeloma KOL.

More details will be available soon.

Mark your calendars for the 22nd IMS Annual Meeting in Toronto, Canada.

The International Myeloma Society Meeting is the defining annual meeting in myeloma with a focus on both the basic, preclinical and the clinical aspects.

The International Myeloma Society Meeting is the defining annual meeting in myeloma with a focus on both the basic, preclinical and the clinical aspects.

More details about this meeting will be shared soon.